AKKARAJU SRINIVAS sold $1.0M of ALMS (indirect holdings)

Alumis (ALMS) stock rose 6.3% in pre-market trading after presenting long-term skin-clearance data for envudeucitinib at the Cantor Fitzgerald Global Healthcare Conference. Management highlighted potential partnerships and insider Srinivas Akkaraju bought 986,000 shares. The FDA application for envudeucitinib is expected in Q4 2026.

AKKARAJU SRINIVAS purchased 986,721 indirectly-held shares of ALUMIS INC. (ALMS) at an average of $10.87 ($10.63–$11.17, $10.73M total) across 4 trades over 2026-09-04 to 2026-09-08.

Alumis Inc. (ALMS) reported that its Phase 2b LUMUS trial of envudeucitinib in systemic lupus erythematosus did not meet primary or secondary endpoints in the overall population. However, a prespecified subgroup with high interferon gene signature showed numerically higher responses. The company plans to discuss Phase 3 trial design with regulators. Envudeucitinib was generally well tolerated.

Alumis Inc. (ALMS) shares dropped 57% after its Phase 2b lupus study missed primary goals, though a patient subgroup showed promising results. The company plans to discuss a late-stage trial with regulators. Wells Fargo and Baird lowered price targets but maintained positive ratings. ALMS is down 3% year-to-date.

Alumis (ALMS) reported its Phase IIb LUMUS trial for envudeucitinib in lupus failed to meet primary and secondary endpoints, causing shares to drop 50%. The trial involved 408 patients and measured disease activity improvement over 48 weeks.

Alumis Inc. (ALMS) reported Phase 2b LUMUS trial results for Envudeucitinib in SLE, missing primary and secondary endpoints overall but showing promise in a subset of patients with high interferon gene signature. The drug demonstrated improvements in several measures in this subgroup and was well tolerated. The company plans to discuss Phase 3 development with regulators. ALMS stock fell over 55% in pre-market trading.